The market growth driven by the increasing prevalence of malaria in endemic regions continues to be a major driver for the market, as the disease remains a significant public health concern in many parts of the world. Leading companies are focusing on the Development of Novel Antimalarial Drugs, Targeted Therapies, Vaccine Development, Drug Delivery Innovations, Point-of-Care Diagnostics, Public Health Interventions, Regulatory Changes, and others to boost market shares in the industry.
The Drugs for Malaria Market challenges such as drug resistance and limited accessibility in low-income regions. Ongoing research focuses on novel antimalarial compounds, combination therapies, and vaccine development, while public health initiatives and international funding play a pivotal role. The market's future hinges on advancements in drug development, diagnostic tools, and vector control strategies to combat the disease effectively.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments across Alliance Pharma PLC, Alvizia Healthcare, Bayer AG, Cadila Healthcare, Cipla Ltd, GlaxoSmithKline Plc, Glenmark Pharmaceuticals, Lincoln Pharmaceuticals, Novartis AG, Strides Pharma Science Ltd, and Others.
The emergence of drug-resistant malaria strains, particularly Plasmodium falciparum, poses a critical challenge to the Drugs for Malaria Market. It necessitates ongoing research to develop new drugs and combination therapies to combat drug resistance effectively and ensure the continued effectiveness of malaria treatment and prevention programs, making it a central concern in the market's evolution.
The Drugs for Malaria Market has a high demand for research and development (R&D) due to the need to address drug resistance, improve treatment, and develop innovative antimalarial solutions. Pharmaceutical companies, research institutions, and global health organizations are actively involved in R&D to discover new drugs and therapies, making it a crucial factor in shaping the market's growth and effectiveness against malaria
Technological advancements in the Drugs for Malaria Market encompass precise diagnostic tools and improved drug delivery methods, enhancing diagnosis accuracy and treatment compliance, and ultimately improving malaria management and control.
The Global Drugs for Malaria Market is analyzed across Aryl amino alcohol compounds, Antifolate compounds, Artemisinin compounds, and others. Of these Artemisinin compounds will register the fastest growth. Artemisinin compounds are essential in the Drugs for Malaria Market, forming the basis of highly effective Artemisinin-based Combination Therapies (ACTs) for treating malaria, including drug-resistant strains. ACTs have significantly reduced malaria-related illness and death. However, concerns about emerging resistance highlight the need for ongoing research and the development of new antimalarial drugs to address this challenge.
The Global Drugs for Malaria Market is analyzed across various End users including Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae, Plasmodium Ovale, and others. Of these, Plasmodium Falciparum held a significant market share in 2024. Plasmodium falciparum is a central focus in the Drugs for Malaria Market due to its high mortality rate in malaria cases. Antimalarial drugs, notably Artemisinin-based Combination Therapies (ACTs), are developed and deployed to treat infections caused by this parasite. However, the emergence of drug-resistant strains of Plasmodium falciparum underscores the need for ongoing research and development to effectively combat this deadly form of malaria.
The US Drugs for Malaria Market size is estimated at $252 Million in 2025. The U.S. drugs for malaria market is driven primarily by its role in global malaria eradication efforts, the demand for prophylactic medications among travelers, and ongoing pharmaceutical R&D for novel antimalarial compounds. While domestic malaria cases are rare, the presence of returning travelers and military personnel from endemic regions fuels the demand for preventive drugs such as atovaquone-proguanil, mefloquine, and doxycycline. The U.S. government, through agencies like the Centers for Disease Control and Prevention (CDC) and the President’s Malaria Initiative (PMI), actively supports malaria research and global drug distribution. Pharmaceutical companies are also engaged in developing next-generation antimalarials to combat drug-resistant Plasmodium strains. However, high drug development costs, stringent FDA regulatory approvals, and limited commercial profitability due to low domestic case numbers pose challenges. Future trends will focus on single-dose curative treatments, long-acting injectable prophylactics, and collaborations with global health organizations to expand access to affordable malaria medications.
Europe Drugs for Malaria Market continues to offer significant business potential with $284 Million sales revenue in 2025. In Europe, the drugs for malaria market is primarily driven by travel medicine, government-backed malaria prevention programs, and research initiatives targeting drug resistance. Countries such as the UK, France, and Germany have high demand for prophylactic antimalarial drugs due to frequent travel to malaria-endemic regions in Africa and Asia. Additionally, Europe plays a crucial role in funding global malaria control programs through institutions such as the Global Fund and the European Medicines Agency (EMA), which fast-tracks approvals for novel malaria treatments. However, concerns over increasing resistance to frontline therapies like artemisinin-based combination therapies (ACTs) have intensified the need for new drug development. The market also faces challenges related to high drug costs and limited commercial incentives for pharmaceutical firms. Future developments will likely focus on innovative combination therapies, vaccine-adjunct treatments, and European partnerships with African and Asian nations for localized drug production and distribution.
South East Asia is among the fastest growing regions worldwide for Drugs for Malaria Market. Over the forecast period to 2034, South East Asia Drugs for Malaria Market demand is poised to register a robust growth rate of 5.2%. Southeast Asia is a key battleground in the fight against malaria, with growing concerns over drug-resistant Plasmodium strains in the Greater Mekong Subregion (GMS). The drugs for malaria market in countries such as Thailand, Vietnam, and Cambodia is shaped by government-led eradication programs, international funding from organizations like WHO and the Gates Foundation, and research into new treatment protocols. Artemisinin resistance remains a critical challenge, leading to increased investment in triple combination therapies and alternative drug regimens. The availability of low-cost generic antimalarials from regional pharmaceutical manufacturers also plays a major role in shaping the market dynamics. However, challenges such as counterfeit drugs, inconsistent rural healthcare access, and fluctuating malaria case numbers complicate efforts to streamline drug distribution. Future trends will center on novel antimalarial drug pipelines, mobile-based malaria surveillance programs, and the integration of AI-driven diagnostic tools to optimize treatment strategies.
Saudi Arabia's drugs for malaria market is driven by the country’s strategic role in malaria elimination efforts, particularly in regions bordering Yemen, where malaria remains endemic. The Saudi government has implemented aggressive vector control programs and drug-based prevention strategies, particularly in high-risk provinces such as Jazan and Asir. Additionally, the annual Hajj pilgrimage, which brings millions of international travelers—including those from malaria-endemic regions—increases the demand for prophylactic treatments. The Ministry of Health ensures access to WHO-approved malaria medications, including ACTs and primaquine for radical cure. However, challenges include managing imported malaria cases, ensuring timely treatment availability in remote areas, and mitigating the risks of resistance to frontline drugs. Future trends will likely involve increased investment in long-term malaria vaccine development, regional collaborations for malaria surveillance, and enhanced public-private partnerships to secure stable drug supplies.
|
Parameter |
Details |
|
Market Size (2025) |
$1.05 Billion |
|
Market Size (2034) |
$1.6 Billion |
|
Market Growth Rate |
4.9% |
|
Segments |
by Drug Class (Aryl amino alcohol compounds, Antifolate compounds, Artemisinin compounds, Others) By Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae, Plasmodium Ovale) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce, Others) |
|
Study Period |
2019- 2024 and 2025-2034 |
|
Units |
Revenue (USD) |
|
Qualitative Analysis |
Porter’s Five Forces, SWOT Profile, Market Share, Scenario Forecasts, Market Ecosystem, Company Ranking, Market Dynamics, Industry Benchmarking |
|
Companies |
Alliance Pharma PLC, Alvizia Healthcare, Bayer AG, Cadila Healthcare, Cipla Ltd, GlaxoSmithKline Plc, Glenmark Pharmaceuticals, Lincoln Pharmaceuticals, Novartis AG, Strides Pharma Science Ltd, and Others. |
|
Countries |
US, Canada, Mexico, Germany, France, Spain, Italy, UK, Russia, China, India, Japan, South Korea, Australia, South East Asia, Brazil, Argentina, Middle East, Africa |
By Drug Class
By Malaria
By Distribution Channel
By Region
* List not exhaustive
Drugs for Malaria Market Outlook 2023
1 Market Overview
1.1 Introduction to the Drugs for Malaria Market
1.2 Scope of the Study
1.3 Research Objective
1.3.1 Key Market Scope and Segments
1.3.2 Players Covered
1.3.3 Years Considered
2 Executive Summary
2.1 2023 Drugs for Malaria Industry- Market Statistics
3 Market Dynamics
3.1 Market Drivers
3.2 Market Challenges
3.3 Market Opportunities
3.4 Market Trends
4 Market Factor Analysis
4.1 Porter’s Five Forces
4.2 Market Entropy
4.2.1 Global Drugs for Malaria Market Companies with Area Served
4.2.2 Products Offerings Global Drugs for Malaria Market
5 COVID-19 Impact Analysis and Outlook Scenarios
5.1.1 Covid-19 Impact Analysis
5.1.2 Post-COVID-19 Scenario- Low Growth Case
5.1.3 Post-COVID-19 Scenario- Reference Growth Case
5.1.4 Post-COVID-19 Scenario- Low Growth Case
6 Global Drugs for Malaria Market Trends
6.1 Global Drugs for Malaria Revenue (USD Million) and CAGR (%) by Type (2018-2030)
6.2 Global Drugs for Malaria Revenue (USD Million) and CAGR (%) by Applications (2018-2030)
6.3 Global Drugs for Malaria Revenue (USD Million) and CAGR (%) by Regions (2018-2030)
7 Global Drugs for Malaria Market Revenue (USD Million) by Type, and Applications (2018-2022)
7.1 Global Drugs for Malaria Revenue (USD Million) by Type (2018-2022)
7.1.1 Global Drugs for Malaria Revenue (USD Million), Market Share (%) by Type (2018-2022)
7.2 Global Drugs for Malaria Revenue (USD Million) by Applications (2018-2022)
7.2.1 Global Drugs for Malaria Revenue (USD Million), Market Share (%) by Applications (2018-2022)
8 Global Drugs for Malaria Development Regional Status and Outlook
8.1 Global Drugs for Malaria Revenue (USD Million) By Regions (2018-2022)
8.2 North America Drugs for Malaria Revenue (USD Million) by Type, and Application (2018-2022)
8.2.1 North America Drugs for Malaria Revenue (USD Million) by Country (2018-2022)
8.2.2 North America Drugs for Malaria Revenue (USD Million) by Type (2018-2022)
8.2.3 North America Drugs for Malaria Revenue (USD Million) by Applications (2018-2022)
8.3 Europe Drugs for Malaria Revenue (USD Million), by Type, and Applications (USD Million) (2018-2022)
8.3.1 Europe Drugs for Malaria Revenue (USD Million), by Country (2018-2022)
8.3.2 Europe Drugs for Malaria Revenue (USD Million) by Type (2018-2022)
8.3.3 Europe Drugs for Malaria Revenue (USD Million) by Applications (2018-2022)
8.4 Asia Pacific Drugs for Malaria Revenue (USD Million), and Revenue (USD Million) by Type, and Applications (2018-2022)
8.4.1 Asia Pacific Drugs for Malaria Revenue (USD Million) by Country (2018-2022)
8.4.2 Asia Pacific Drugs for Malaria Revenue (USD Million) by Type (2018-2022)
8.4.3 Asia Pacific Drugs for Malaria Revenue (USD Million) by Applications (2018-2022)
8.5 South America Drugs for Malaria Revenue (USD Million), by Type, and Applications (2018-2022)
8.5.1 South America Drugs for Malaria Revenue (USD Million), by Country (2018-2022)
8.5.2 South America Drugs for Malaria Revenue (USD Million) by Type (2018-2022)
8.5.3 South America Drugs for Malaria Revenue (USD Million) by Applications (2018-2022)
8.6 Middle East and Africa Drugs for Malaria Revenue (USD Million), by Type, Technology, Application, Thickness (2018-2022)
8.6.1 Middle East and Africa Drugs for Malaria Revenue (USD Million) by Country (2018-2022)
8.6.2 Middle East and Africa Drugs for Malaria Revenue (USD Million) by Type (2018-2022)
8.6.3 Middle East and Africa Drugs for Malaria Revenue (USD Million) by Applications (2018-2022)
9 Company Profiles
10 Global Drugs for Malaria Market Revenue (USD Million), by Type, and Applications (2023-2030)
10.1 Global Drugs for Malaria Revenue (USD Million) and Market Share (%) by Type (2023-2030)
10.1.1 Global Drugs for Malaria Revenue (USD Million), and Market Share (%) by Type (2023-2030)
10.2 Global Drugs for Malaria Revenue (USD Million) and Market Share (%) by Applications (2023-2030)
10.2.1 Global Drugs for Malaria Revenue (USD Million), and Market Share (%) by Applications (2023-2030)
11 Global Drugs for Malaria Development Regional Status and Outlook Forecast
11.1 Global Drugs for Malaria Revenue (USD Million) By Regions (2023-2030)
11.2 North America Drugs for Malaria Revenue (USD Million) by Type, and Applications (2023-2030)
11.2.1 North America Drugs for Malaria Revenue (USD) Million by Country (2023-2030)
11.2.2 North America Drugs for Malaria Revenue (USD Million), by Type (2023-2030)
11.2.3 North America Drugs for Malaria Revenue (USD Million), Market Share (%) by Applications (2023-2030)
11.3 Europe Drugs for Malaria Revenue (USD Million), by Type, and Applications (2023-2030)
11.3.1 Europe Drugs for Malaria Revenue (USD Million), by Country (2023-2030)
11.3.2 Europe Drugs for Malaria Revenue (USD Million), by Type (2023-2030)
11.3.3 Europe Drugs for Malaria Revenue (USD Million), by Applications (2023-2030)
11.4 Asia Pacific Drugs for Malaria Revenue (USD Million) by Type, and Applications (2023-2030)
11.4.1 Asia Pacific Drugs for Malaria Revenue (USD Million), by Country (2023-2030)
11.4.2 Asia Pacific Drugs for Malaria Revenue (USD Million), by Type (2023-2030)
11.4.3 Asia Pacific Drugs for Malaria Revenue (USD Million), by Applications (2023-2030)
11.5 South America Drugs for Malaria Revenue (USD Million), by Type, and Applications (2023-2030)
11.5.1 South America Drugs for Malaria Revenue (USD Million), by Country (2023-2030)
11.5.2 South America Drugs for Malaria Revenue (USD Million), by Type (2023-2030)
11.5.3 South America Drugs for Malaria Revenue (USD Million), by Applications (2023-2030)
11.6 Middle East and Africa Drugs for Malaria Revenue (USD Million), by Type, and Applications (2023-2030)
11.6.1 Middle East and Africa Drugs for Malaria Revenue (USD Million), by Region (2023-2030)
11.6.2 Middle East and Africa Drugs for Malaria Revenue (USD Million), by Type (2023-2030)
11.6.3 Middle East and Africa Drugs for Malaria Revenue (USD Million), by Applications (2023-2030)
12 Methodology and Data Sources
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Sources
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Disclaimer
List of Tables
Table 1 Market Segmentation Analysis
Table 2 Global Drugs for Malaria Market Companies with Areas Served
Table 3 Products Offerings Global Drugs for Malaria Market
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Drugs for Malaria Revenue (USD Million) And CAGR (%) By Type (2018-2030)
Table 8 Global Drugs for Malaria Revenue (USD Million) And CAGR (%) By Applications (2018-2030)
Table 9 Global Drugs for Malaria Revenue (USD Million) And CAGR (%) By Regions (2018-2030)
Table 10 Global Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Table 11 Global Drugs for Malaria Revenue Market Share (%) By Type (2018-2022)
Table 12 Global Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Table 13 Global Drugs for Malaria Revenue Market Share (%) By Applications (2018-2022)
Table 14 Global Drugs for Malaria Market Revenue (USD Million) By Regions (2018-2022)
Table 15 Global Drugs for Malaria Market Share (%) By Regions (2018-2022)
Table 16 North America Drugs for Malaria Revenue (USD Million) By Country (2018-2022)
Table 17 North America Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Table 18 North America Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Table 19 Europe Drugs for Malaria Revenue (USD Million) By Country (2018-2022)
Table 20 Europe Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Table 21 Europe Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Table 22 Asia Pacific Drugs for Malaria Revenue (USD Million) By Country (2018-2022)
Table 23 Asia Pacific Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Table 24 Asia Pacific Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Table 25 South America Drugs for Malaria Revenue (USD Million) By Country (2018-2022)
Table 26 South America Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Table 27 South America Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Table 28 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Region (2018-2022)
Table 29 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Table 30 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Table 31 Financial Analysis
Table 32 Global Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Table 33 Global Drugs for Malaria Revenue Market Share (%) By Type (2023-2030)
Table 34 Global Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Table 35 Global Drugs for Malaria Revenue Market Share (%) By Applications (2023-2030)
Table 36 Global Drugs for Malaria Market Revenue (USD Million), And Revenue (USD Million) By Regions (2023-2030)
Table 37 North America Drugs for Malaria Revenue (USD)By Country (2023-2030)
Table 38 North America Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Table 39 North America Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Table 40 Europe Drugs for Malaria Revenue (USD Million) By Country (2023-2030)
Table 41 Europe Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Table 42 Europe Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Table 43 Asia Pacific Drugs for Malaria Revenue (USD Million) By Country (2023-2030)
Table 44 Asia Pacific Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Table 45 Asia Pacific Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Table 46 South America Drugs for Malaria Revenue (USD Million) By Country (2023-2030)
Table 47 South America Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Table 48 South America Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Table 49 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Region (2023-2030)
Table 50 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Region (2023-2030)
Table 51 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Table 52 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Table 53 Research Programs/Design for This Report
Table 54 Key Data Information from Secondary Sources
Table 55 Key Data Information from Primary Sources
List of Figures
Figure 1 Market Scope
Figure 2 Porter’s Five Forces
Figure 3 Global Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Figure 4 Global Drugs for Malaria Revenue Market Share (%) By Type (2022)
Figure 5 Global Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Figure 6 Global Drugs for Malaria Revenue Market Share (%) By Applications (2022)
Figure 7 Global Drugs for Malaria Market Revenue (USD Million) By Regions (2018-2022)
Figure 8 Global Drugs for Malaria Market Share (%) By Regions (2022)
Figure 9 North America Drugs for Malaria Revenue (USD Million) By Country (2018-2022)
Figure 10 North America Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Figure 11 North America Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Figure 12 Europe Drugs for Malaria Revenue (USD Million) By Country (2018-2022)
Figure 13 Europe Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Figure 14 Europe Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Figure 15 Asia Pacific Drugs for Malaria Revenue (USD Million) By Country (2018-2022)
Figure 16 Asia Pacific Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Figure 17 Asia Pacific Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Figure 18 South America Drugs for Malaria Revenue (USD Million) By Country (2018-2022)
Figure 19 South America Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Figure 20 South America Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Figure 21 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Region (2018-2022)
Figure 22 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Type (2018-2022)
Figure 23 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Applications (2018-2022)
Figure 24 Global Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Figure 25 Global Drugs for Malaria Revenue Market Share (%) By Type (2030)
Figure 26 Global Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Figure 27 Global Drugs for Malaria Revenue Market Share (%) By Applications (2030)
Figure 28 Global Drugs for Malaria Market Revenue (USD Million) By Regions (2023-2030)
Figure 29 North America Drugs for Malaria Revenue (USD Million) By Country (2023-2030)
Figure 30 North America Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Figure 31 North America Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Figure 32 Europe Drugs for Malaria Revenue (USD Million) By Country (2023-2030)
Figure 33 Europe Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Figure 34 Europe Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Figure 35 Asia Pacific Drugs for Malaria Revenue (USD Million) By Country (2023-2030)
Figure 36 Asia Pacific Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Figure 37 Asia Pacific Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Figure 38 South America Drugs for Malaria Revenue (USD Million) By Country (2023-2030)
Figure 39 South America Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Figure 40 South America Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Figure 41 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Region (2023-2030)
Figure 42 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Region (2023-2030)
Figure 43 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Type (2023-2030)
Figure 44 Middle East and Africa Drugs for Malaria Revenue (USD Million) By Applications (2023-2030)
Figure 45 Bottom-Up and Top-Down Approaches For This Report
Figure 46 Data Triangulation
By Drug Class
By Malaria Type
By Distribution Channel
By Region
The Global Drugs for Malaria Market Size is estimated at $1.05 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 4.9% to reach $1.6 Billion by 2034.
The US Drugs for Malaria Market size is estimated at $252 Million in 2025.
Alliance Pharma PLC, Alvizia Healthcare, Bayer AG, Cadila Healthcare, Cipla Ltd, GlaxoSmithKline Plc, Glenmark Pharmaceuticals, Lincoln Pharmaceuticals, Novartis AG, Strides Pharma Science Ltd, and Others.
Base Year- 2024; Estimated Year- 2025; Historic Period- 2019-2024; Forecast period- 2025 to 2034; Currency: Revenue (USD); Volume
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.